Kytril

Selected form

Granisetron

Method of action: Antiemetic

Treatment option: Radiation Therapy, Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kytril

What is Kytril? (Granisetron) Overview

Property	Description
Active Ingredient	Granisetron (as hydrochloride salt)
Form	Oral tablet, Oral solution, Injection, Transdermal system
Pharmacological Class	Serotonin 5-HT3 receptor antagonist
Common Use	Prophylaxis (prevention) of nausea and vomiting
Origin	Synthetic small molecule

What Type of Medicine is Kytril? (Definition and Classification)

Kytril is a synthetic, prescription-only medicine whose active component is the substance Granisetron, typically formulated as Granisetron hydrochloride. It is classified within the pharmacological class of Serotonin 5-HT3 receptor antagonists, also known as selective 5-HT3 blockers. This substance acts as an antiemetic, a highly targeted compound designed to interrupt a specific neurochemical signal pathway involved in the vomiting reflex.

Composition and Available Forms

Kytril is a single-ingredient product, relying solely on Granisetron (as the hydrochloride salt) for its effect. The medicine is prepared in several distinct dosage forms to accommodate various administration needs, including the standard oral tablet and oral solution for oral use, and a solution for injection for parenteral administration. Granisetron is also available in a transdermal system, or skin patch, offering an extended-release, non-oral method of delivery; this particular form is utilized when oral intake is compromised or continuous prevention is required.

Kytril's General Purpose and Benefit

The general purpose of Kytril is to serve as a prophylactic agent, specifically by preventing episodes of nausea and vomiting before they start. It achieves this by causing inhibition of serotonin binding at the 5-HT3 receptors, which are crucial sites that transmit the emetic signal from the body to the brain. Its antiemetic activity against chemically-induced nausea provides preemptive relief from the signal to vomit. Granisetron is frequently utilized as the preferred agent for preventing emesis in patient groups undergoing specific treatments where the rapid and substantial release of serotonin is anticipated.

What side effects are possible with Kytril?

The safety profile of Kytril (Granisetron) is established through official regulatory documents, which classify adverse reactions by frequency and the body system affected. All documented effects and safety notes are derived from authoritative government sources.

Adverse Reactions by Classification

The most frequently documented side effects are categorized as Very Common (may affect more than 1 in 10 people) and include Headache (a Nervous system disorder) and Constipation (a Gastrointestinal disorder). Reactions classified as Common (may affect up to 1 in 10 people) include Insomnia and Diarrhoea.

Less frequent, or Uncommon, adverse reactions noted in official labeling include Hypersensitivity reactions (e.g., rash) and changes in heart rhythm, specifically QT prolongation as seen on an ECG, a finding associated with Cardiac disorders.

Serious Adverse Reactions and Safety Notes

The regulatory profile identifies specific serious adverse reactions. These include Serotonin Syndrome, a potentially life-threatening event that may be more likely with the co-administration of other serotonergic medicines (such as SSRIs or SNRIs). Severe Hypersensitivity Reactions, including anaphylaxis, are also documented as rare occurrences.

Safety Considerations are noted for specific populations. Caution is advised for patients with pre-existing cardiac conditions or electrolyte abnormalities due to the potential for QT prolongation. Furthermore, the antiemetic effect of Granisetron may mask signs of a sub-acute intestinal obstruction or gastric distension, which is a relevant note for patients post-abdominal surgery. Kytril is contraindicated in patients with a known hypersensitivity to the drug or any of its components.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented overdose profile and mandated emergency actions for Kytril (Granisetron), based strictly on government regulatory documents.

Category	Regulatory Documentation Summary
Documented Overdose Presentations	Overdoses, including instances of large single doses up to 38.5 mg, have been reported in official documents to result in minimal symptoms. The most frequently noted manifestation is a mild headache, though some cases report no symptoms whatsoever.
Physiological Systems Affected	Regulator-documented risks are noted for the Cardiovascular system (e.g., QT prolongation which necessitates continuous monitoring) and the Central Nervous System (potential for Serotonin Syndrome and seizures). Patients are also required to be monitored for signs of masked sub-acute intestinal obstruction.
Population-Specific Overdose Notes	Based on pharmacokinetic reviews, no special precautions are required for the elderly or those with renal or hepatic impairment regarding overdose risk.
Emergency-Response Statements	Seek emergency medical attention immediately for any suspected overdose, even if asymptomatic. The official instruction is to call emergency services (911) if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The Poison Control Helpline must also be contacted promptly.

Official Overdose Structure

Official regulatory documents establish that no specific antidote is known for Kytril overdosage; therefore, clinical management is strictly symptomatic and supportive. The mandatory help-seeking conditions are designed to ensure prompt initiation of monitoring, even when the patient is asymptomatic, due to the inherent, documented potential for severe complications like cardiac conduction abnormalities and Serotonin Syndrome that may not be immediately apparent.

Therapeutic Uses of Kytril

Kytril (Granisetron) is a specialized medication focused on providing prophylactic anti-sickness support in acute clinical settings. It plays a role in managing symptoms that may lead to episodes of nausea and vomiting, which generally contributes to improved comfort during challenging treatments.

The medication is commonly used to help manage symptoms that create noticeable physiological strain associated with specific medical interventions. Its main therapeutic domains include supportive management during highly emetogenic chemotherapy and radiation therapy, as well as the control of postoperative nausea and vomiting (PONV).

Prevention of Sickness from Cancer Treatments

This domain covers the medication's use in managing the intense acute and delayed symptoms of sickness associated with cancer treatments. It is applied across therapeutic areas involving heightened responses, and supports the easing of the symptom burden during clinical treatment phases. Using Kytril in this context provides supportive symptomatic relief that may help patients cope more steadily with difficult episodes and assists with maintaining functional stability during symptomatic periods.

Control of Post-Procedural Emetic Symptoms

Kytril is also relevant in clinical settings marked by procedurally-induced symptom expression. It is used across domains where short-term symptomatic assistance is appropriate, assisting with managing symptoms that interfere with daily functioning. This provides support that contributes to easing the overall symptom load.

Quick Fact: Relief for Acute Nausea and Vomiting Kytril is considered relevant when supportive symptom management is appropriate for symptoms that create noticeable physiological strain during temporary periods of medical stress.

Regulatory References

European Medicines Agency (EMA) information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Kytril (Granisetron)

Official regulatory documents define strict population eligibility for Kytril. Use is contraindicated in patients with a known hypersensitivity to granisetron or to any other 5-HT3 receptor antagonist, as well as those with allergies to the formulation's excipients. Kytril is generally approved for use in adults and older adults, where no age-related dosage adjustment is typically required.

Population Group	Regulatory Eligibility Status (Per Label)
Pediatric Patients (under 2 years)	Safety and effectiveness are not established
Children (2 years and older)	Permitted for IV injection in acute chemotherapy-induced nausea and vomiting (CINV); Oral forms are not recommended
Hepatic Impairment	Conditional Use: Caution should be exercised, though no standard dose adjustment is needed
Renal Impairment	Permitted Use: No special precautions or dose adjustment is required
Pregnancy/Lactation	Conditional Use: Use during pregnancy is recommended only if clearly needed; breastfeeding is generally not advised

Special Caution is required for patients with pre-existing cardiac conditions (e.g., arrhythmias) or signs of sub-acute intestinal obstruction, as stated in prescribing information.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Kytril

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Serotonergic Drugs (e.g., SSRIs, SNRIs, MAOIs) and Drugs known to prolong the QT interval. CYP450 Enzyme Inducers/Inhibitors
Specific interacting medicines (if explicitly listed)	Apomorphine, Phenobarbital, Ketoconazole
Mechanistic basis of interactions (only if stated in label)	Inhibition of ring oxidation (Ketoconazole), Change the clearance and half-life (CYP Inducers/Inhibitors), Additive QT prolongation
Timing-based interaction rules (if applicable)	Kytril Injection should not be mixed in solution with other drugs
Population-specific interaction notes (if applicable)	Hepatically Impaired Patients (total clearance approximately halved)
Interaction-related restrictions	Contraindicated with Apomorphine; Associated with Serotonin Syndrome (Serotonergic Drugs)

Interaction Classifications (High-Level)

Category	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated (Apomorphine). Risk associated with concomitant use (Serotonergic Drugs, QT-prolonging drugs)
Regulatory basis	US FDA Prescribing Information, Health Canada Product Monograph, EMA Summary of Product Characteristics (SmPC)
Interaction-context constraints (as defined in official documents)	Food increases C max by 30% for oral tablets. Heat increases plasma concentrations for the transdermal system

Resulting Interaction Structure

Official regulatory documents define the product's interaction structure based on two primary pharmacodynamic risks—the potential for additive QT prolongation and the association with Serotonin Syndrome when combined with serotonergic agents. The most stringent restriction is the official regulatory statement that the combination with Apomorphine is contraindicated due to the risk of profound hypotension.

The profile also documents pharmacokinetic effects, noting that the CYP enzyme inducer Phenobarbital increases intravenous Granisetron's total plasma clearance by approximately 25%. Furthermore, the ingestion of food with the oral tablet is documented to increase the C max by 30%, and total clearance is approximately halved in patients with hepatic impairment.

Mechanism of Action

Kytril's active ingredient, Granisetron, is a highly selective competitive antagonist for the Serotonin (5-HT)3 receptor, which is a ligand-gated ion channel. The mechanism acts at two critical anatomical sites: the vagal afferent nerve terminals in the gastrointestinal (GI) tract and the neurons of the Chemoreceptor Trigger Zone (CTZ) in the brainstem. By binding to these 5-HT3 receptors, the drug physically blocks the natural neurotransmitter serotonin from activating the channel. This specific molecular interaction prevents the necessary ion flux (cation influx) required for the nerve cells to generate an electrical impulse. The dual central and peripheral action effectively interrupts the fundamental afferent signal that transmits emetic information to the Medullary Vomiting Center. This cascade results in a strong physiological modulation of the serotonin-mediated response. However, due to its high selectivity, the mechanism does not address physiological responses driven by other mediators, such as those involved in motion sickness or the delayed emetic phase.

Dosage and Administration Information

Kytril (granisetron) is administered according to specific regimens to ensure proper timing relative to the clinical event. It is available for use via Oral (tablet, solution), Intravenous (IV) (injection, infusion), Transdermal (patch), and Subcutaneous (SC) (extended-release injection) routes.

Official Dosing and Administration

Administration Route	Standard Adult Dosing (Prophylaxis)	Timing and Duration	Population-Specific Rules
Oral (Tablet/Solution)	1 mg BID or 2 mg QD	First dose taken up to 1 hour before chemotherapy/radiation; regimen may continue for up to 7 days.	No adjustment needed for older adults, renal, or hepatic impairment.
Intravenous (IV)	10 mcg/kg or 1 mg (up to 3 mg)	Administered within 30 minutes before chemotherapy; infusion over 5 minutes or undiluted over 30 seconds.	Pediatric (2-16 yrs): 10 mcg/kg IV dose.
Transdermal (Patch)	One patch releasing 3.1 mg/24 hours	Applied 24 to 48 hours before chemotherapy; worn for up to 7 days; removed a minimum of 24 hours after completion.	Safety and efficacy not established in pediatric patients.

Contextual Use Instructions

Oral administration is not influenced by food. IV injection preparation may require dilution with approved solutions (0.9% Sodium Chloride or 5% Dextrose) and must be administered according to specified infusion times. The transdermal patch must be applied to clean, dry skin on the outer part of the upper arm.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Kytril (Granisetron)

Evidence for use in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV)

Research exploring the use of Kytril was studied for sickness related to chemotherapy, which has been a primary focus of the evidence base. These studies generally involved Randomized Controlled Trials (RCTs), where patients were assigned by chance to receive either Kytril, a placebo, or another anti-sickness medication. The research examined its application in populations undergoing treatments classified as having a high or moderate potential to cause sickness.

The studies monitored outcomes related to physical discomfort. Specifically, researchers measured the rate of Complete Response (no vomiting or retching and no need for rescue medication). This outcome was tracked during the initial acute phase and the delayed phase following chemotherapy. Studies monitored whether results were generally more consistent for evaluating the acute phase of CINV compared to the delayed phase.

Evidence for use in Managing Postoperative Nausea and Vomiting (PONV)

Kytril was also studied in conditions characterized by acute or disruptive episodes of sickness following surgery. The research primarily consisted of Randomized, Double-Blind, Placebo-Controlled Trials that evaluated the medicine’s application in the context of PONV. Studies examined outcomes capturing phases of heightened symptom activity, typically during the 24 hours immediately following the procedure.

The primary focus of the findings was the measurement of Complete Response in the immediate postoperative setting. The follow-up durations for these studies were limited, focusing on the first day after the procedure. Limited research is available for the use of the oral tablet form in the context of PONV prevention.

Research Gaps and Remaining Uncertainties

Official reviews acknowledge certain areas where the evidence is still developing or where data are insufficient. Long-term effects are not fully established, and evidence for continuous use or outcomes years later remains limited. Comparative evidence against newer anti-sickness treatments is sometimes lacking in the literature base. Data for certain groups, such as patients with pre-existing conditions or those receiving specialized treatments, remain insufficient compared to the primary studied populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Kytril (FAQ)

Q: Is Kytril a medicine used for general or specific types of nausea and vomiting?

Kytril (granisetron) is officially indicated for the prevention of nausea and vomiting caused by specific medical treatments. According to regulatory documents, the primary approved uses are for preventing sickness associated with chemotherapy, radiation therapy, and in some forms, postoperative recovery. It is not generally indicated for all types of sickness.

Q: What are the main conditions Kytril is officially indicated to prevent or treat?

The official regulatory indications for Kytril are primarily the prevention of nausea and vomiting associated with chemotherapy and radiation therapy. This information comes directly from official prescribing labels.

Q: Is Kytril effective for nausea that is already present?

Kytril's main purpose, according to official information, is to work as a prophylactic agent, meaning it is given to prevent nausea and vomiting before they start. However, the official prescribing information for the injection form does state that a single dose may also be administered to treat established nausea and vomiting in adults in specific clinical settings.

Q: What is Serotonin Syndrome, and is it a possible complication of Kytril use?

Serotonin syndrome is a potentially serious condition associated with Kytril, particularly when taken with other medicines that affect serotonin levels. Official safety information lists signs such as agitation, confusion, a fast heart rate, and loss of muscle coordination. This condition results from excessive serotonin activity in the nervous system.

Q: What antidepressant medications are known to interact with Kytril?

Official labeling notes that Kytril may interact with medicines that increase serotonin levels, which includes certain types of antidepressants such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs). This combination carries a risk of Serotonin Syndrome.

Q: Are there any specific heart medications that should be avoided while using Kytril?

Official regulatory information advises caution when using Kytril alongside other medicines known to prolong the QT interval. This includes certain antiarrhythmic or heart medications, as there is a potential for an additive effect on the heart's rhythm.

Q: How long is the effect of Kytril expected to last after one dose?

Regulatory documents indicate that the average terminal phase plasma half-life of granisetron in adult cancer patients is approximately 9 hours, though this can vary widely. The half-life describes the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: What signs might indicate a serious allergic reaction to Kytril?

Official safety data documents serious hypersensitivity reactions. Signs of a serious allergic reaction may include hives, swelling of the face, tongue, or throat, or difficulty breathing. Official labeling warns about these symptoms as potentially serious.

Q: Is dizziness or lightheadedness a known side effect of Kytril?

Yes, regulatory documents list dizziness as a common side effect of the oral form of Kytril, and a less common side effect of other forms. This falls under the category of nervous system disorders.

Q: Are there reported psychological side effects, such as anxiety or agitation?

Yes, the official regulatory profile includes agitation and anxiety among the common psychiatric adverse reactions reported with Kytril use.

Q: Can Kytril cause unusual tiredness or a feeling of weakness?

Official labeling notes that asthenia (lack of strength) and unusual tiredness or weakness are common side effects reported in clinical trials.

Q: Is there a possibility of fever being linked to Kytril use?

Yes, fever is listed in the regulatory profile as a common side effect.

Q: Are changes in appetite or taste reported with Kytril?

Official labeling includes reports of decreased appetite and a change in the sense of taste, known as taste disorder, as common adverse events.

Q: Does Kytril have a known interaction with alcohol?

Official patient information states that the use of alcoholic beverages must be avoided while using the product.

Q: Are there any warnings about changes to liver enzyme levels while using Kytril?

Yes, elevations in liver enzymes, specifically AST and ALT (transaminases), have been reported as common adverse events in clinical trials.

How should Kytril be stored and disposed of?

Official Storage and Disposal Instructions

The required storage conditions for Kytril (granisetron) are strictly defined by regulatory documents to maintain product stability.

Item	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (25 C / 77 F) with allowed excursions (15 C to 30 C).
Environmental	The product must be Protected from light and the injection must not freeze.
Container Rule	Oral tablet containers must be kept tightly closed.
Stability Limit	Multi-use vials must be used within 30 days after first penetration. Diluted solutions are stable for at least 24 hours at room temperature.
Child Safety	All forms must be kept out of the sight and reach of children.
Disposal	Do not dispose of unused medicine via wastewater or household waste. Ask your pharmacist how to throw away expired or unused product.